Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan Q Notti

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Cancer Research|June 18, 2025
XPO1 R749Q Mutations Co-occur with POLE Mutations in Cancer and Can Be Targeted to Overcome ChemoresistanceTulasigeri M Totiger, Wannasiri Chiraphapphaiboon, Yasmine Baca, et al.
The New England Journal of Medicine|February 23, 2022
Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase InhibitorsEric Wang, Xiaoli Mi, Meghan C Thompson, et al.
Science (New York, N.Y.)|February 1, 2024
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127Skye Montoya, Jessie Bourcier, Mark Noviski, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Cancer Research|June 18, 2025
XPO1 R749Q Mutations Co-occur with POLE Mutations in Cancer and Can Be Targeted to Overcome ChemoresistanceTulasigeri M Totiger, Wannasiri Chiraphapphaiboon, Yasmine Baca, et al.
The New England Journal of Medicine|February 23, 2022
Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase InhibitorsEric Wang, Xiaoli Mi, Meghan C Thompson, et al.
Science (New York, N.Y.)|February 1, 2024
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127Skye Montoya, Jessie Bourcier, Mark Noviski, et al.
Pageof 2